Participants in the study will be randomly assigned to receive either BHV-7000 or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for about eight weeks, during which participants will take the medication or placebo daily. Researchers will monitor the participants to see if there is a reduction in the number of seizures they experience. The goal is to find out if BHV-7000 can help reduce seizures by at least 50% in those taking the medication compared to those taking the placebo.

Throughout the study, the safety and tolerability of BHV-7000 will be closely observed. This means researchers will keep track of any side effects or adverse reactions participants might experience. The study aims to provide valuable information on whether BHV-7000 can be a beneficial treatment option for people with Refractory Focal Onset Epilepsy, potentially offering a new way to manage this challenging condition.

The purpose of this study is to assess how well XEN1101 works in reducing the number of seizures experienced by participants. Participants will be randomly assigned to receive either XEN1101 or a placebo. The study will last for a period of 12 weeks, during which participants will take the capsules daily. Throughout the study, participants will be monitored to see if there is a reduction in the frequency of their seizures and to evaluate the safety and tolerability of the medication.

This trial is designed to provide valuable information on the potential benefits of XEN1101 as an additional treatment for people with focal onset seizures. The results will help determine if XEN1101 can be an effective option for managing this type of epilepsy. Participants will be required to keep a diary of their seizures to help researchers understand the impact of the treatment. The study aims to contribute to the development of new therapies for individuals living with epilepsy.

The study examines how well probenecid works in stopping additional seizures when patients are undergoing special brain monitoring with video-EEG. During this monitoring, patients’ regular anti-seizure medications may be reduced to allow doctors to better observe and record their seizures. The medication or placebo will be given by mouth when cluster seizures occur during the monitoring period.

Doctors will observe patients for 12 hours after receiving the study medication to see if it prevents more seizures from occurring. They will also monitor other important factors such as changes in brain electrical activity, heart rate, blood pressure, and any side effects that might occur. The monitoring includes continuous recording of both video and brain wave patterns to ensure accurate observation of any seizure activity.

The study aims to determine how safe and well-tolerated vormatrigine is when given to patients who have previously received this medication in other studies or through special access programs. The medication comes in the form of capsules that are taken by mouth. The treatment period may last up to 24 months.

During the study, doctors will monitor patients’ health through various tests and check how well the medication is working to control seizures. They will pay special attention to any side effects that might occur during treatment and measure the amount of medication in patients’ blood. The study will also track changes in the severity of the condition as observed by both doctors and patients.

During the study, participants will be assigned to receive either PRAX-628 or a placebo. This is done through a process called randomization, where groups are chosen by chance to ensure the results are fair. The study is also double-blind, meaning that neither the participants nor the researchers know which treatment is being given until the study is over. The process involves an initial observation period to record the current number of seizures, followed by a treatment period where the effects of the medication are studied.

The purpose of this research is to evaluate how well SPN-817 works as a treatment for adults with focal onset seizures, and to assess its safety and how well patients tolerate it. During the study, participants will receive either SPN-817 or placebo while continuing to take their current anti-seizure medications.

The treatment will involve taking capsules by mouth daily for several months. The medication dose may be adjusted during the initial period of the study, followed by a maintenance period where the dose remains stable. Throughout the study, participants will need to keep track of their seizures using an electronic diary and attend regular check-ups where their health will be monitored through various assessments.

Participants in the study will receive Cenobamate in increasing doses to see how their bodies handle the medication over time. The study will involve both single doses and multiple doses to gather comprehensive information. Throughout the study, the safety and tolerability of Cenobamate will be closely monitored, which means researchers will watch for any side effects or reactions to the medication. Additionally, the study will collect information on how often seizures occur while taking the medication.

The study aims to provide valuable insights into the use of Cenobamate for treating Partial-Onset Seizures in children and teenagers. By understanding how the medication works in younger patients, researchers hope to improve treatment options for those affected by this condition. Participants will be under careful observation to ensure their safety and well-being throughout the study period.

The purpose of the study is to evaluate how effective PRAX-628 is in reducing the frequency of these seizures. Participants in the study will take PRAX-628 in the form of a capsule, which is taken orally. The study will last for a period of up to eight weeks, during which participants will continue their usual anti-seizure medications while adding PRAX-628 to their treatment plan. The study will monitor changes in seizure frequency and any side effects experienced by participants.

Throughout the study, participants will be asked to keep a diary of their seizures and any changes they notice. The study aims to see if PRAX-628 can help reduce the number of seizures and improve the overall quality of life for those affected by these types of epilepsy. The results will help determine the safety and effectiveness of PRAX-628 as a potential new treatment option for people with these seizure disorders.

The purpose of the study is to see if BHV-7000 can help reduce the number of seizures experienced by participants. Participants will be randomly assigned to receive either one of the two doses of BHV-7000 or a placebo. The study will last for about 12 weeks, during which participants will take the medication daily and keep a record of their seizures. The goal is to find out if at least half of the participants experience a significant reduction in their seizure frequency.

Throughout the study, the safety and tolerability of BHV-7000 will be closely monitored. Participants will have regular check-ups to assess their health and any side effects they may experience. The study aims to provide valuable information on whether BHV-7000 can be a beneficial treatment option for those with Refractory Focal Onset Epilepsy.

The study will involve taking the medication in the form of a capsule, which is taken orally. The active ingredient in XEN1101 is called azetukalner. The trial will last for a period of time, during which participants will be monitored for changes in their seizure frequency and any side effects they may experience. The goal is to see if XEN1101 can help reduce the number of seizures and to ensure it is safe for use.

Participants will be required to keep a diary of their seizures and attend regular check-ups to assess their health and the medication’s effects. The study includes an open-label extension, meaning that after the initial phase, all participants may have the opportunity to receive XEN1101 if they wish. This trial is an important step in finding new ways to manage focal epilepsy and improve the quality of life for those affected by this condition.

Participants in the study will receive the medication BHV-7000 over a period of time to see how well it is tolerated and to monitor any side effects. The study will also include a comparison with a placebo to better understand the effects of the medication. The trial is designed to be long-term, lasting up to 52 weeks, to gather comprehensive data on the safety of the treatment.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to collect information on any changes in their condition. The ultimate goal is to determine if BHV-7000 can be a safe and effective treatment option for individuals with refractory focal onset epilepsy, potentially offering a new avenue for managing this challenging condition.

The purpose of the study is to evaluate how well children tolerate cenobamate and to observe any side effects that may occur. Participants in the study will receive cenobamate in different forms, including oral suspension and tablets, with varying doses such as 12.5mg, 25mg, 50mg, and 100mg. The study will last for up to 12 months, during which the children will be monitored for any changes in their seizure frequency and overall health. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of cenobamate.

Throughout the study, researchers will track the number of seizures, any side effects, and changes in behavior or development. They will also assess the acceptability and taste of the medication forms. The goal is to gather information that could help improve treatment options for children with partial-onset seizures in the future.

The purpose of this study is to understand how safe and tolerable long-term use of XEN1101 is for people with epilepsy. Participants in the study will take the medication over a period of time, and researchers will monitor them to see how they respond to the treatment. This includes looking at any side effects they might experience and how their seizure frequency changes. The study will also assess the overall impact on participants’ quality of life and any changes in their health over time.

Throughout the study, participants will be asked to take the medication regularly and attend scheduled check-ups. These check-ups will help researchers gather important information about the medication’s effects. The study aims to provide valuable insights into the long-term use of XEN1101 for managing epilepsy, which could help improve treatment options for people living with this condition.

During the study, participants will take the medication in the form of tablets or capsules by mouth. The treatment period will last for up to eight weeks, during which the effects of the medication on seizure frequency will be closely monitored. The goal is to determine if ENX-101 can help reduce the number of seizures experienced by participants compared to those taking the placebo.

The study will also look at how many participants become seizure-free during the last 28 days of the treatment period and throughout the entire treatment period. This research is important for finding new ways to help people with focal epilepsy manage their condition more effectively.

The study will involve taking EQU-001 in the form of a soft capsule, which is taken orally. The trial will last for several weeks, during which participants will continue their usual epilepsy medications. The study will include a period where participants’ seizure activity is observed and recorded. This will help researchers understand how EQU-001 affects seizure frequency and whether it provides any additional benefits over the current treatment.

Throughout the study, participants will be asked to keep a diary of their seizures and any changes they notice. This information will be used to assess the effectiveness of EQU-001 in managing focal onset seizures. The trial aims to provide valuable insights into whether this new treatment can help people with epilepsy who continue to experience seizures despite being on medication.

Participants in the study will be randomly assigned to receive either XEN1101 or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for a period of 12 weeks, during which participants will take the medication or placebo daily. Throughout the study, participants will be monitored for any changes in their seizure frequency and any side effects they may experience.

The study aims to provide valuable information on the safety and effectiveness of XEN1101 as an additional treatment for people with focal onset seizures. By comparing the results between those taking XEN1101 and those taking the placebo, researchers hope to determine if XEN1101 can significantly reduce the number of seizures and improve the quality of life for individuals with this condition. The findings from this study could potentially lead to new treatment options for people living with focal onset seizures.

The purpose of the study is to evaluate how well PRAX-628 works in reducing the number of seizures experienced by participants. The study will be conducted over a period of several weeks, during which participants will be randomly assigned to receive either PRAX-628 or a placebo. Participants will continue their current anti-seizure medications throughout the study. The trial will involve regular monitoring and assessments to track changes in seizure frequency and any side effects experienced by participants.

Participants will be asked to keep a diary of their seizures and attend scheduled visits for assessments. The study aims to provide valuable information on the safety and effectiveness of PRAX-628 as a potential treatment option for individuals with Focal Epilepsy. This research could lead to improved management of seizures for those affected by this condition.